EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis

Lin Yue, Yuting Li, Cailing Gan, Meng Sun, Conghui Deng, Taixiong Xue, Yuting Xie, Hongyao Liu, Zhihao Liu, Tinghong Ye

Bioorganic Chemistry · 2026-08 · 178 · 109945

DOI: 10.1016/j.bioorg.2026.109945 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-08. Verfasst von Lin Yue und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of High Altitude Medicine, Center for High Altitude Medicine, Department of Emergency Medicine, Institute of Disaster Medicine and Institu…. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Receptor, Transforming Growth Factor-beta Type I, Drug Design, Protein Kinase Inhibitors. Die Arbeit nennt 43 Literaturangaben. Gefördert von: West China Hospital of Sichuan University, Science and Technology Department of Sichuan Province, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary fibrosis (PF) is a progressive and fatal lung disease characterized by excessive extracellular matrix (ECM) deposition, leading to irreversible scarring and respiratory failure. With limited treatment options, there is an urgent need for novel therapeutic strategies. Activin receptor-like kinase 5 (ALK5), a type I receptor serine/threonine kinase, serves as the principal mediator of transforming growth factor-β (TGF-β) signaling and a pivotal driver of PF pathogenesis. Given the central role of ALK5 in fibrogenesis, targeting ALK5 represents a promising therapeutic approach. Conventional ALK5 inhibitors primarily target kinase activity, whereas proteolysis-targeting chimeras (PROTACs) may offer a promising therapeutic strategy by inducing degradation of the target protein. Herein, we report the discovery of a series of novel ALK5-targeting PROTAC degraders. The lead compound, A31, induced ALK5 degradation in NIH3T3 cells and demonstrated inhibition of ALK5 downstream signaling and fibroblast activation. Furthermore, A31 exhibits favorable pharmacokinetics following intraperitoneal administration, in vivo anti-fibrotic efficacy, and no significant toxicity at efficacious doses. Collectively, our study supports the feasibility of ALK5-targeting degradation as a potential therapeutic strategy for pulmonary fibrosis and highlights the therapeutic potential of PROTAC-based strategies in fibrotic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary FibrosisReceptor, Transforming Growth Factor-beta Type IDrug DesignProtein Kinase InhibitorsAnimalsMiceProteolysis Targeting ChimeraNIH 3T3 CellsHumansStructure-Activity RelationshipMolecular StructureProteolysisDose-Response Relationship, Drug

Stichwörter der Autor:innen

A31ALK5PROTACPulmonary fibrosisTGF-β

Substanzen

Receptor, Transforming Growth Factor-beta Type IProteolysis Targeting ChimeraProtein Kinase InhibitorsTGFBR1 protein, human

Autor:innen und Institutionen

  • Department of High Altitude Medicine, Center for High Altitude Medicine, Department of Emergency Medicine, Institute of Disaster Medicine and Institute of Emergency Medicine, State Key Laboratory of Biotherapy, West Chi…

Förderung

  • West China Hospital of Sichuan University
  • Science and Technology Department of Sichuan Province
  • Sichuan University
  • National Natural Science Foundation of China

Zitieren

APA

Yue, L., Li, Y., Gan, C., Sun, M., Deng, C., Xue, T., Xie, Y., Liu, H., Liu, Z., & Ye, T. (2026). Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis. Bioorganic Chemistry, 178, 109945. https://doi.org/10.1016/j.bioorg.2026.109945

Vancouver

Yue L, Li Y, Gan C, Sun M, Deng C, Xue T, et al. Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis. Bioorganic Chemistry. 2026;178:109945. doi:10.1016/j.bioorg.2026.109945

BibTeX
@article{Yue2026,
  author = {Yue, Lin and Li, Yuting and Gan, Cailing and Sun, Meng and Deng, Conghui and Xue, Taixiong and Xie, Yuting and Liu, Hongyao and Liu, Zhihao and Ye, Tinghong},
  title = {Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {178},
  pages = {109945},
  doi = {10.1016/j.bioorg.2026.109945}
}
Kostenlos starten →